SNMMI 2019 Mid-Winter Meeting

January 17 – January 19, 2019

Renaissance Palm Springs Palm Springs, CA

Molecular and Genomic Theranostics in Thyroid Cancer:
The Evolving Role for Nuclear Medicine
Thursday, January 17, 2019 1:30pm-3:30pm

Course overview

This 2-hour session will provide an overview of genetics of thyroid cancer and discussion of the molecular testing. It will review the role of molecular testing in the differential diagnosis of thyroid nodules. The surgical treatment planning based on molecular pathology will be discussed. Also, the rationale and clinical role for RAI treatment will be discussed in the context of the theranostic value of genomics and molecular profiling, with special reference to I-124 PET/CT imaging and dosimetry.

CME objectives

The CME objectives are to discuss:

1) The basic principles of molecular testing for thyroid nodules 2) The role of molecular profiling as a theranostic tool for initial treatment of thyroid cancer 3) The role for postoperative RAI imaging and ablation in the context of the theranostic value of genomics and molecular profiling, with special reference to I-124 PET/CT imaging and dosimetry

CME need Justification:

Molecular profiling has made an impactful entry in the care of patients with thyroid nodules and thyroid cancer. RAI imaging and treatment principles are being redefined based on the new molecular pathology information. There is a need for reconfiguring the role for Nuclear Medicine in this changing paradigm

Session Organizer: Seza Gulec

Moderator: Bennett Greenspan

- Genomic Theranostics of Thyroid Cancer for Surgery and Nuclear Medicine: Seza Gulec, MD
- Appropriate use of RAI Treatment Postoperatively: Anca Avram, MD
- Metastatic Thyroid Cancer RAI Resistance and Remedies: Mark Tulchinsky, MD
- Radioactive Iodine Theranostics and Dosimetry: Seza Gulec